Transtympanic injection of a liposomal gel loaded with N-acetyl-L-cysteine: A relevant strategy to prevent damage induced by cochlear implantation in guinea pigs?

Glutathione Hyaluronic acid Inner ear Local drug delivery N,N’-diacetyl-L-cystine Oxidative stress

Journal

International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127

Informations de publication

Date de publication:
15 Jul 2021
Historique:
received: 25 02 2021
revised: 26 05 2021
accepted: 27 05 2021
pubmed: 1 6 2021
medline: 28 7 2021
entrez: 31 5 2021
Statut: ppublish

Résumé

Patients with residual hearing can benefit from cochlear implantation. However, insertion can damage cochlear structures and generate oxidative stress harmful to auditory cells. The antioxidant N-acetyl-L-cysteine (NAC) is a precursor of glutathione (GSH), a powerful endogenous antioxidant. NAC local delivery to the inner ear appeared promising to prevent damage after cochlear implantation in animals. NAC-loaded liposomal gel was specifically designed for transtympanic injection, performed both 3 days before and on the day of surgery. Hearing thresholds were recorded over 30 days in implanted guinea pigs with and without NAC. NAC, GSH, and their degradation products, N,N'-diacetyl-L-cystine (DiNAC) and oxidized glutathione (GSSG) were simultaneously quantified in the perilymph over 15 days in non-implanted guinea pigs. For the first time, endogenous concentrations of GSH and GSSG were determined in the perilymph. Although NAC-loaded liposomal gel sustained NAC release in the perilymph over 15 days, it induced hearing loss in both implanted and non-implanted groups with no perilymphatic GSH increase. Under physiological conditions, NAC appeared poorly stable within liposomes. As DiNAC was quantified at concentrations which were twice as high as NAC in the perilymph, it was hypothesized that DiNAC could be responsible for the adverse effects on hearing.

Identifiants

pubmed: 34058306
pii: S0378-5173(21)00562-7
doi: 10.1016/j.ijpharm.2021.120757
pii:
doi:

Substances chimiques

Liposomes 0
Acetylcysteine WYQ7N0BPYC

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

120757

Informations de copyright

Copyright © 2021. Published by Elsevier B.V.

Auteurs

Céline Jaudoin (C)

Université Paris-Saclay, CNRS, Institut Galien Paris-Saclay, 5 rue J-B Clément, 92296 Châtenay-Malabry, France. Electronic address: celine.jaudoin@universite-paris-saclay.fr.

Fabienne Carré (F)

Inserm/Institut Pasteur, Institut de l'audition, Technologies et thérapie génique pour la surdité, 63 rue de Charenton, 75012 Paris, France. Electronic address: fabienne.carre@aphp.fr.

Maria Gehrke (M)

Université Paris-Saclay, CNRS, Institut Galien Paris-Saclay, 5 rue J-B Clément, 92296 Châtenay-Malabry, France. Electronic address: m.s.gehrke@hotmail.de.

Audrey Sogaldi (A)

UMS IPSIT, SAMM, Faculté de Pharmacie, Université Paris-Saclay, 5 rue J-B Clément, 92296 Châtenay-Malabry, France. Electronic address: audrey.solgadi@universite-paris-saclay.fr.

Vincent Steinmetz (V)

Université Paris-Saclay, CNRS, Institut de Chimie des Substances Naturelles, UPR 2301, 91198 Gif-sur-Yvette, France. Electronic address: vincent.steinmetz@cnrs.fr.

Nathalie Hue (N)

Université Paris-Saclay, CNRS, Institut de Chimie des Substances Naturelles, UPR 2301, 91198 Gif-sur-Yvette, France. Electronic address: nathalie.hue@cnrs.fr.

Catherine Cailleau (C)

Université Paris-Saclay, CNRS, Institut Galien Paris-Saclay, 5 rue J-B Clément, 92296 Châtenay-Malabry, France. Electronic address: catherine.cailleau@universite-paris-saclay.fr.

Guillaume Tourrel (G)

Oticon Medical/Neurelec SAS, Research & Technology Department, 2720 chemin Saint-Bernard, Vallauris, France. Electronic address: GUTO@oticonmedical.com.

Yann Nguyen (Y)

Inserm/Institut Pasteur, Institut de l'audition, Technologies et thérapie génique pour la surdité, 63 rue de Charenton, 75012 Paris, France; Sorbonne Université, AP-HP, GHU Pitié-Salpêtrière, DMU ChIR, Service ORL, GRC Robotique et Innovation Chirurgicale, 47-83, boulevard de l'hôpital, 75013 Paris, France. Electronic address: yann.nguyen@inserm.fr.

Evelyne Ferrary (E)

Inserm/Institut Pasteur, Institut de l'audition, Technologies et thérapie génique pour la surdité, 63 rue de Charenton, 75012 Paris, France. Electronic address: evelyne.ferrary@inserm.fr.

Florence Agnely (F)

Université Paris-Saclay, CNRS, Institut Galien Paris-Saclay, 5 rue J-B Clément, 92296 Châtenay-Malabry, France. Electronic address: florence.agnely@universite-paris-saclay.fr.

Amélie Bochot (A)

Université Paris-Saclay, CNRS, Institut Galien Paris-Saclay, 5 rue J-B Clément, 92296 Châtenay-Malabry, France. Electronic address: amelie.bochot@universite-paris-saclay.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH